340
SupramoleculeS in Drug DiScovery anD Drug Delivery: methoDS anD protocolS
Index
Compositional homogeneity ��136
Compositions �� 26, 37, 101, 136, 146,
159, 203, 227, 288, 308
Compounds �� 2, 5, 37, 38, 40, 42, 94,
95, 109–111, 146, 155, 163, 165, 176, 180, 182,
183, 185, 191, 204, 238, 239, 249, 251, 254, 255,
271, 274, 278, 285–288, 292, 293, 313–315, 319,
333–335, 337
Computational chemistry �� 54, 110
Computational protocol ��45–69
Concentrations ��3, 5, 22, 30, 35, 37,
40, 41, 69, 74, 81, 88, 90, 92, 93, 96, 99, 102, 129,
135–137, 141, 143, 147–149, 155, 156, 160, 167,
176, 180, 182, 184, 189, 191, 194, 195, 212, 214,
217, 227, 230, 231, 237, 249–253, 256, 258,
266–268, 276–278, 286, 288, 289, 292, 293, 301,
309, 319
Confocal ��95–96, 254, 261
Conjugation �� 17, 19–20, 235, 329, 330
Constant pressure �� 57, 117, 118, 171, 230
Controlled drug release�� 87, 203, 204
Cooperativity �� 300, 303, 305, 307, 309
Co-precipitation �� 2, 3, 164
Covalent coupling ��14–15
Critical micelle concentration (CMC) �� 99, 102, 274
Crystalline state �� 168, 171, 231
Curcumin (CRM) ��4, 5, 7, 72–74, 76–78, 80, 251
Cyclodextrin (CD) ��1–4, 6, 8, 9, 35, 37,
42, 46, 49, 50, 53, 59, 61, 64, 68, 109–123, 164,
167–171, 188, 190, 191, 194, 195, 247–279,
287–289, 294–296, 304, 305, 313–322
Cyclodextrin inclusion ��2
Cytotoxicity ��72, 90, 92, 93, 176, 184,
238, 249, 251, 256, 266, 328, 329
D
Damp mixing and heating ��3
Degree of substitution (DS) ��188, 194, 236, 272
Dendrimers ��299, 300, 303, 305, 308, 309
Deuterated solvents �� 101, 317, 337
Diagnosis �� 25, 151, 221
Dialysis �� 35–40, 42, 87–90, 143, 145, 146,
206, 209–211
1,6-Diaminohexane ��129, 135, 140, 146
Differential power (DP) ��189, 192, 195, 196
Differential scanning calorimetry (DSC) �� 163–172,
222–227, 229, 230, 248, 250, 251, 253, 273,
299–309
Diffusion coefficients ��238, 239, 244, 245, 288, 289
Diffusion- ordered NMR spectroscopy ��239
Difunctional initiator �� 130, 142
3D structure �� 136, 137
Dipalmitoyl-phosphatidylcholine (DPPC) �� 222–229,
231, 304–308, 316, 318–321, 323
1,2-dipalmitoyl-sn-glycero-3-phosphocholine
(DPPC) �� 222–224, 227–229, 231,
304–308, 316, 318–320
Dispersion phase ��210
Dispersions �� 14, 19, 20, 72, 90, 142, 154,
163, 165, 206, 207, 245, 259, 264, 267, 276, 301,
303, 304, 306, 319
Doxorubicin ��87, 89, 139, 140, 145, 253
5-doxyl-stearic acid (5-DSA) ��101, 102, 105, 106
DPPC bilayers �� 225, 304, 306, 319, 321
Drug
absorption ��4, 45, 76–78, 89, 90, 96,
100, 160, 315, 328
CD complexes, 288
delivery ��1–9, 13–22, 25, 71–81,
85–96, 99, 100, 109–123, 139–149, 151, 152, 155,
164, 188, 203–204, 206, 207, 221, 222, 231,
235–245, 248, 252, 254, 258, 267, 268, 271, 279,
300, 313, 315, 316, 328
encapsulations ��238, 248, 271
formulations��13, 73, 79, 80, 100, 101, 110,
188, 190, 202–205, 244, 276, 328
loading, 76, 77, 86, 87, 90, 99, 155, 175, 192, 260
localization�� 95
molecules �� 4, 5, 37, 46, 48–52, 57, 62,
64, 68, 87, 99, 102, 155, 165, 204–206, 222, 267,
269, 287, 288, 299, 300, 303, 315, 317
membrane interactions �� 318
Drug delivery system (DDS) ��13, 85–88, 90,
99–107, 136, 137, 199, 202–207, 211, 251, 269, 308
Dry mixing ��4
Dynamic light scattering (DLS) �� 35, 79, 81, 141,
148, 222, 224, 227, 228, 231, 249
E
Electron microscopy ��28, 29, 156, 157
Electrostatic association ��14
Electrostatic interactions �� 189, 260, 274
Encapsulated curcumin �� 78, 81
Encapsulation of indomethacin �� 76, 80
Encapsulation processes ��71
Encapsulation protocols �� 72, 73, 79
Encapsulations �� 20, 71–81, 86, 155, 156,
175–185, 188, 191, 248, 252, 256, 258, 259,
265–267, 271, 273, 274, 276, 277
Endocytosis �� 14, 88
Endothermic peak �� 168, 169, 303
Endothermic process �� 171, 196
Energetics ��46, 110, 117–118
Enhancement of the aqueous solubility ��4
Enthalpy �� 2, 117, 118, 122, 168, 189, 307, 308
Enthalpy changes �� 167, 168, 171, 189, 192,
195, 225, 302
Entrapment efficiency �� 258, 269, 272, 315, 324

- 340/344